Literature DB >> 21617558

Five consecutive cases of a cutaneous vasculopathy in users of levamisole-adulterated cocaine.

Korey Ullrich1, Robert Koval, Erin Koval, Srinivas Bapoje, Joel M Hirsh.   

Abstract

Five patients with an antineutrophil cytoplasmic antibody (ANCA)-associated cutaneous vasculopathy secondary to levamisole-adulterated cocaine were prospectively followed up at a single hospital. All patients presented with retiform purpura, with ear involvement being the most characteristic finding. Cocaine metabolites were present on urine toxicology screening, with 2 of 4 of those tested also being positive for levamisole. High-titer polyspecific ANCA and positive antiphospholipid antibody tests were defining laboratory features. Thrombosis and/or leukocytoclastic vasculitis were seen on skin biopsy. Improvement of skin lesions and laboratory findings occurred with cessation of cocaine; however, arthralgias and other complications developed. Levamisole-adulterated cocaine is a cause of a cutaneous vasculopathy associated with characteristic laboratory and clinical features that allow it to be distinguished from classic ANCA-associated small-vessel vasculitides. The chronic sequelae of this syndrome and the potential role for immunosuppression are yet to be completely defined.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21617558     DOI: 10.1097/RHU.0b013e31820e6822

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  18 in total

Review 1.  Lupus anticoagulant and ANCA associated thrombotic vasculopathy due to cocaine contaminated with levamisole: a case report and review of the literature.

Authors:  Shuchi Gulati; Anthony A Donato
Journal:  J Thromb Thrombolysis       Date:  2012-07       Impact factor: 2.300

Review 2.  Cutaneous vasculopathy associated with levamisole-adulterated cocaine.

Authors:  Huy Tran; Debbie Tan; Thomas P Marnejon
Journal:  Clin Med Res       Date:  2012-06-21

Review 3.  Cocaine-Levamisole-Induced Vasculitis/Vasculopathy Syndrome.

Authors:  Javier Marquez; Lina Aguirre; Carolina Muñoz; Andres Echeverri; Mauricio Restrepo; Luis F Pinto
Journal:  Curr Rheumatol Rep       Date:  2017-06       Impact factor: 4.592

4.  Levamisole and cocaine synergism: a prevalent adulterant enhances cocaine's action in vivo.

Authors:  Christopher S Tallarida; Erin Egan; Gissel D Alejo; Robert Raffa; Ronald J Tallarida; Scott M Rawls
Journal:  Neuropharmacology       Date:  2014-01-15       Impact factor: 5.250

5.  Levamisole enhances the rewarding and locomotor-activating effects of cocaine in rats.

Authors:  Christopher S Tallarida; Ronald J Tallarida; Scott M Rawls
Journal:  Drug Alcohol Depend       Date:  2015-02-07       Impact factor: 4.492

6.  Cocaine-induced vasculitis: clinical and immunological spectrum.

Authors:  Luis R Espinoza; Rodolfo Perez Alamino
Journal:  Curr Rheumatol Rep       Date:  2012-12       Impact factor: 4.592

7.  Levamisole-induced occlusive necrotising vasculitis in cocaine abusers: an unusual cause of skin necrosis and neutropenia.

Authors:  Cassius D Belfonte; Victoria K Shanmugam; Nicole Kieffer; Shodeinde Coker; Suelyn Boucree; Gail Kerr
Journal:  Int Wound J       Date:  2012-06-21       Impact factor: 3.315

8.  Complications associated with use of levamisole-contaminated cocaine: an emerging public health challenge.

Authors:  Kachiu C Lee; Barry Ladizinski; Daniel G Federman
Journal:  Mayo Clin Proc       Date:  2012-06       Impact factor: 7.616

9.  Levamisole-Contaminated Cocaine Use in HIV-Infected and Uninfected Unstably Housed Women.

Authors:  Elise D Riley; Alex H Kral; Jennifer Cohen; Samantha E Dilworth; Martha Shumway; Kara L Lynch
Journal:  J Womens Health (Larchmt)       Date:  2016-05-20       Impact factor: 2.681

10.  Levamisole-induced leukocytoclastic vasculitis and neutropenia in a patient with cocaine use: an extensive case with necrosis of skin, soft tissue, and cartilage.

Authors:  Natasha Purai Arora; Tania Jain; Ravinder Bhanot; Suganthini Krishnan Natesan
Journal:  Addict Sci Clin Pract       Date:  2012-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.